Eledon Pharmaceuticals, Inc. ELDN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
0/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$45.6M | — | — | $81.1M |
| 2024 | — | -$36.2M | — | — | $62.4M |
| 2023 | — | -$116.5M | — | — | -$48.5M |
| 2022 | — | -$88.0M | — | — | $84.2M |
| 2021 | — | -$34.5M | — | — | $164.0M |
| 2020 | — | -$22.8M | — | — | $190.6M |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001404281 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.